Prof. Joseph Levine

Senior Psychiatrist

Publication List

LIST OF SCIENTIFIC PUBLICATIONS – Also available at Google Scholar


  1. Fennig S, Levin Y, Naisberg S, Elizur A. The effect of trihexyphenidyl on memory functions of schizophrenic patients. Prog. Neuro-Psychopharmacol. & Biol. Psychiat., Vol. 11, pp. 71-78, 1986
  2. Levin Y, Elizur A. Korczyn AD. Physostigmine improves ECT induced memory disturbances. Neurology, Vol. 37, pp. 871-875, 1987
  3. Levin Y, Salgenik I, Etzion T, Levy A, Neumann M, Korczyn AD. Naloxone fails to improve post ECT memory and cognitive disturbances. Brain Dysfunction, Vol. 3, pp. 193-196, 1990
  4. Eitan N, Levin Y, Levy A, Neumann M. The effects of antipsychotic drugs on memory function of schizophrenic patients. Acta Psychiat, Scand., Vol. 85, pp. 74-7, 1992
  5. Levine J, Swartz M, Schrieber G. Premedication with non-selective and M1-selective muscarinic antagonists before ECT. Isr. J. Psychiat, Vol. 30, pp. 179-182, 1993
  6. Agam G, Levine J, Steir S, Schield C, Bersudsky Y, Belmaker RH. Short term lithium treatment does not reduce CSF inositol levels. Lithium, Vol. 4, pp. 267-269, 1993
  7. Levine J, Rapaport A, Lev L, Bersudsky Y, Kofman O, Belmaker RH, Shapiro J, Agam G. Inositol treatment raises CSF inositol levels. Brain Research, Vol. 627, pp. 168-190, 1993
  8. Levine J, Goldberge I, Rapaport A, Swart M, Schield C, Elizur A, Belmaker RH, Shapiro J, Agam G. CSF inositol levels in schizophrenia are unchanged and inositol is not therapeutic in schizophrenia. Eur. Neuropsychopharmacol. Vol. 4, pp. 487-490, 1994
  9. Levine J, Umansky R, Ezrielev G. Belmaker RH. Lack of effect of inositol treatment in chronic schizophrenia. Biol. Psychiat., Vol. 33, pp. 673-675, 1993
  10. Levine J, Gonsalves M, Babur I, Stir S, Elizur A, Kofman O, Belmaker RH. Inositol, 6gm daily, may be effective in depression but not in schizophrenia. Human Psychopharacology, Vol. 8, pp. 49-53, 1993
  11. Nachshoni T, Levin Y, Levy A, Nuemann M. A double-blind trial of carbamazepine in negative symptoms of schizophrenia. Biological Psychiatry, Vol. 35, pp. 22-26, 1994.
  12. Levine J, Roisman I, Nisman B, Barak V, Barak Y. Changes in interleukin -1b and soluble interleukin 2 receptor levels in CSF and serum of schizophrenic patients. Journal of Basic and Clinical Physiology and Pharmacology, Vol. 6, pp. 61-70, 1995
  13. Barak Y, Levine J, Lampel A, Elizur A. Delirium during heroin withdrawal with doxepine: A double blind study. Human Psychopharmacology , Vol. 10, pp. 149-151, 1995
  14. Levine J, Barak Y, Gonsalves M, Szor H, Elizur A, O.Kaufman O, RH.Belmarker. Double blind study of inositol versus placebo in depression. Am.J.Psychiat , Vol. 152, pp. 792-794, 1995
  15. Levine J, Barak Y., Belmaker RH. Follow up study of inositol treatment for depression. Israel J.Psychiatry, Vol. 32, pp. 14-21, 1995
  16. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Inositol treatment of panic disorder. Am. J. Psychiat., Vol. 152, pp. 1084-1086, 1995
  17. Levine J, Pomerantz T, Stier S, Belmaker RH. The effect of 6gm inositol treatment on post-ECT cognitive function in humans. Journal of Psychiatric Research, Vol. 29, pp. 487-489, 1996
  18. Kaplan Z ,Amir M, Swartz M, Levine J. Inositol treatment of PTSD Anxiety, Vol. 2, pp. 51-52, 1996
  19. Levine J, Ring A, Barak Y, Elizur A, Belmaker RH. Inositol in attention deficit disorder with hyperactivity. Human Psychopharmacology, Vol. 10, pp. 481-84, 1996
  20. Barak Y, Stein D, Levine J, Ring A, Hadjez J, Elizur A, D. Shoshani D. Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly: An open trial. Human Psychopharmacology, Vol. 11, 463-67, 1996
  21. Levine J, Schild K, Kimhi R, Shreiber G. Word associative production in affective versus schizophrenic psychoses. Psychopathology, Vol. 29, pp. 7-13, 1996
  22. Kaplan Z , Schild K , Levine J. Violence in hospitalized psychiatric patients: diurnal and seasonal patterns. Psychiatry Research, Vol. 60, pp. 199-204, 1996
  23. Moldavsky D, Levine J, Elizur A. Requalifying, examination and employment in immigrant physicians as predictors of successful immigration in Israel. Isr. J. Psychiat., Vol. 33, pp. 50-53, 1996
  24. Levine J, Rapoport A , Mashiah M, Dolev E. Serum and cerbrospinal levels of calcium and magnesium in acute versus remitted schizophrenic patients. Neuropsychobiology, Vol. 33, pp. 169-172, 1996
  25. Barak Y, Levine J, Glasman A, Elizur A, Belmaker RH. Inositol treatment of Alzhiemer disease .Progress in Neuropsychopharmacology, Vol. 20, pp. 729-735, 1996
  26. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obssesive compulsive disorder. Am. J. Psychiatry, Vol. 153, pp. 1219-221, 1996
  27. Levine J, Aviram A, Holan A, Ring A, Barak Y, Belmaker RH. Inositol treatment of autism. J Neural Transmission, Vol. 104, pp. 307-10, 1997
  28. Levine J, Kurtzman L, Rapoport A, Zimmerman J, Bersudsky Y, Shapiro J, Belmaker RH, Agam G. CSF inositol does not predict antidepressant response to inositol. J Neural Transmission, Vol. 103, pp. 1457-1463, 1997
  29. Levine J, Shechtman T , Lefkifker E, Horesh N, Agam G, Bersudsky Y. Inositol may reverse lithium induced polydipsia but not polyuria. Human Psychopharmacology, Vol. 12, pp. 459-65, 1997
  30. Amir M, Kaplan Z, Ephroni R, Levine J, Benjamin J, Kotler M. Coping styles in posttraumatic stress disorder (PTSD) patients. Personality and Individual Differences Vol. 23, pp. 399-405, 1997
  31. Levine J, Martin T, Feraro R, Kimhi R, Bracha SH. Medicated chronic schizophrenic patients do not demonstrate left turning asymmetry. Neuropsychobiology, Vol. 36, pp. 22-24, 1997
  32. Levine J, Caspi N, Laufer N. Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word associations of schizophrenic patients. Schizophrenia Research, Vol. 26, pp. 55-63, 1997
  33. Levine J, Gutman J, Feraro R, Levy P, Kimhi R, Leykin I, Deckmann M, Handzel ZT, Shinitzky M. Side effects profile of azathioprine in the treatment of chronic schizophrenic patients. Neuropsychobiology, Vol. 36, pp. 172-6, 1997
  34. Levine J, Barak Y, Granek I. Cognitive group therapy for paranoid schizophrenic patients: Applying cognitive dissonance. Cognitive Psychotherapy, Vol. 12, pp. 3- 12, 1998
  35. Roitman G, Levine J, Bersudsky Y, Belmaker RH. An adenylate cyclase inhibitor in the treatment of excited psychosis. Human Psychopharmacology, Vol. 13, pp. 121-5, 1998
  36. Ebstein RP, Levine J, Geller V, Aurbach J, Gritsenko I, Belmaker RH. The dopamine D4 receptor (D4DR) exon III repeat polymorphism and the serotonin promoter region polymorphism in the determination of neonatal temperament of two-weeks old infants. Molecular psychiatry, Vol. 3, pp. 238-46, 1998
  37. Rapoport A, Stein D, Shamir E, Schwartz M, Levine J, Elizur A, Weizman A. Clinico-tremorgraphic features of neuroleptic-induced tremor. International Clinical Psychopharmacology, Vol. 13, pp. 115-120, 1998
  38. Doron A, Stein D, Levine J, Avramovitch Y, Eilat E, Neuman M. Physiological reactions to a suicide film: suicide attempters, suicide ideators and nonsuicidal patients. -Suicide and Life Threatening Behavior, Vol. 28, pp. 309-314, 1998
  39. Gavrilov V, Levine J, Agam G, Belmaker RH. Lithium enhancement of the prolactin response to 5-hydroxytryptophan is not reversible by inositol. Progress in Neuropsychopharmacology & Biological Psychiatry, Vol. 22, pp. 523-28, 1998
  40. Einat H, Levine J, Grauer E, MacDonald K, Belmaker RH. Effects of inositol treatment on the behavior of Macaque monkeys. Progress in Neuropsychopharmacology & Biological Psychiatry, Vol. 22, pp. 999-1005,1998
  41. Atack JR, Levine J, Belmaker RH. Cerebrospinal fluid inositol monophosphatase: Elevated activity in schizophrenia and depression.Biological Psychiatry, Vol. 44, pp. 433-37, 1998
  42. Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of inositol and serotonin reuptake inhibitor in the treatment of depression. Biological Psychiatry, Vol. 45, pp. 270-273, 1999
  43. Rapoport A, Stein D, Swartz M, Levine J, Stier S, Elizur A, Rabey JM. A trial of L-deprenyl for the treatment of neuroleptic-induced parkinsonism. J Neural Transmission, Vol. 106, pp. 911-918, 1999
  44. Levine J, Stein D, Rapoport A, Kurtzman L. High serum and cerebrospinal Ca/Mg ratio in recently hospitalized acute depressed patients. Neuropsychobiology, Vol. 39, pp. 63-70, 1999
  45. Chengappa KRN, Ebelng T, Kang S, Levine J, Parapelly H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry, Vol. 60, pp. 477-84, 1999
  46. Auerbach J, Getter V, Letzer S, Shinwell R, Belmaker RH and Levine J and Ebstein RP. Dopamine D4 receptor (D4DR) and serotonin transporter promoter (5-HTTLPR) polymorphisms in the determination of temperament in two month old infants. Molecular Psychiatry, Vol. 4, pp. 378-384, 1999
  47. Levine J, Barak Y, Chengappa KRN, Rapoport A, Rebey M, Barak V. Acute cerebrospinal cytokine levels in depressed patients. Neuropsychobiology, Vol. 40, pp. 171-176, 1999
  48. Levine J. Barak, K. R. N. Chengappa, A. Rapoport, S. Antelman, V. Barak. Low CSF soluble interleukin 2 receptor levels in acute depression . J Neural Transmission, Vol. 106, pp. 1011-1015, 1999
  49. Chengappa KNR, Rathore D, Levine J, Atzert R, Solai L, Parepally H, Moffa N, Delaney J, Brar JS. Topiramate as add-on adjuctive treatment for patients with bipolar I or schizoaffective disorder – bipolar type experiencing manic or mixed episodes. Bipolar Disorders, Vol. 1, pp. 42-53, 1999
  50. Mishory A, Levine J, Kahana E, Belmaker RH. Inositol is not therapeutic in Parkinson's disease. Human Psychopharmacology, Vol. 14, pp. 271-272, 1999
  51. Nemetz B, Mishori A, Levine J, Belmaker RH. Inositol addition does not improve depression in SSRI treatment failures, Journal of Neural Transmission, Vol. 106, pp. 795-798, 1999
  52. Levine J, Chengappa KRN, Reddy R. Acute myo-inositol enhances swimming activity in goldfish. J Neural Transmission, Vol. 106, pp. 433-441, 1999.
  53. Chengappa KRN, Levine J, Gershon S , Mallinger AG, Hardan A, Vagnucci A, Pollock B., Luther J, Kupfer DJ. Inositol in Bipolar Depression: A pilot, double-blind, placebo-controlled, random assignment clinical trial. Bipolar Disorders, Vol. 2, pp. 47-55, 2000
  54. Chengappa KRN, Pollock B, Parepally H, Levine J, Kirschner M, Brar J, Zoretich R. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clinical Psychopharmacology, 20, pp. 3121-316, 2000
  55. Rapoport A, Sade H M. Stein D, Levine J, Sirota P, Mosheva T, Stir S, Elizur A, Geva D, Resnik I, Rabey M. Botolinum toxin for the treatment of perioral tardive dyskinesia. Movement Disorders, Vol. 15, pp. 352-5, 2000
  56. Levine J , Panchaligam K, McClure RJ, Rapoport A, Gershon S and Pettegrew JW. High glutamine levels in CSF of depressed patients. Biological Psychiatry, Vol. 47, pp. 586-593, 2000
  57. Levine J, Chengappa KRN, Brar JS, Gershon S, Yablonsky E, Stapf D, Kupfer DJ. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disorders, Vol. 2, pp. 120-130, 2000
  58. Antelman SM, Levine J, Gershon S. Time dependent sensitization: the odyssey of a scientific heresy from the laboratory to the door of the clinic. Molecular Psychiatry, Vol. 5, pp. 350-6, 2000
  59. Chengappa KRN, Levine J, Gershon S, Kupfer DJ. Life-time prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders Bipolar Disorders, Vol. 2, pp. 191-195, 2000
  60. Meiran N, Levine J, Henik A, Meiran N. 3:41-9. Task switching in schizophrenia. Neuropsychology, Vol. 14, pp. 471-82, 2000
  61. Levine J, Pachalingam K, McClure RJ, Gershon S and Pettegrew JW. Stability of CSF metabolites measured by proton NMR. Journal of Neural Transmission, Vol. 107, pp. 843-8, 2000
  62. Pettegrew JW, Levine J, McClure D. Metabolic and physical-chemical properties of L-acetylcarnitine: are they responsible for its effects in Alzheimer, and geriatric depression? Molecular Psychiatry, Vol. 5, pp. 616-32, 2000
  63. Chengappa KRN, Levine J, Jaspret SB, Parepally H, Brenzo R, Zoretich R, Aretz R, Palmer A, Gopalani A. Impact of risperidone on seclusions and restraints at a state psychiatric hospital. Canadian Journal of Psychiatry, Vol. 45, pp. 827-32, 2000
  64. Maoz G, Stein D, Meged S, Valevsky A, Kurzman L, Levine J, Aviv A, Sirota P, Kraus R, Weizman A, Berger BD. The anti-aggressive action of combined haloperidol- propanolol tretment in schizophrenia. American Psychologist, Vol. 5, pp. 312-315, 2000
  65. Chengappa KN, Levine J , Rathore D, Parepally H, Atzert R. Long term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry, Vol. 16, pp. 186-90, 2001
  66. Pettegrew JW, Pachalingam K, Levine J , Muclure RJ, Gershon S, Yao JK. Chronic myo-inositol increases rat brain phosphatidylethanolamine plasmalogen. Biol Psychiatry, Vol. 49, pp. 444-53, 2001
  67. Gelber D, Levine J, Belmaker RH. Effect of inositol on bulimia nervosa and binge eating. Int J Eat Disord., Vol. 29, pp. 345-8, 2001
  68. Levine J, Chengappa KRN, Brar J, Gershon S, Kupfer DJ. Illness characteristics and their association with prescription patterns for bipolar I disorder. Bipolar Disorders, Vol. 3, pp. 41-9, 2001
  69. KNR Chengappa, M Tohen, Levine J, T Jacobs, M Thase, TM Sanger, DJ Kupfer. Response to placebo or olanzapine among bipolar disorder patients experiencing their first manic episode. Bipolar disorders, Vol. 2, pp. 332-5, 2001
  70. Pettegrew JW, Panchalingam K, McClure RJ, Gershon S and Levine J. Effects of chronic lithium administration on rat brain phosphatidylinositol cycle constituents, membrane glycerolipids and amino acids. Bipolar Disorders, Vol. 3, pp. 189-201, 2001
  71. Chengappa NKR, Kambhampati RK, Perkins K. Nigam R, Anderson T, Vemulappalli HK, Azert R, Key P, Kang JS, Brar J and Levine J. Bupropion SR as a smoking aid in remitted depressed patients maintained on selective serotonin reuptake inhibitor antidepressants. J Clinical Psychiatry, Vol. 62, pp. 503-8, 2001
  72. Auerbach J, Faroy M, Ebstein R, Kahana M, Geller V and Levine J. The association of the D4 receptor gene (DRD4) and the serotonin transporter promoter gene (5-HTTLPR) with temperament in 12-month old infants. J Child Psychology & Psychiatry, Vol. 42, pp. 777-83, 2001
  73. Pettegrew JW, Panchalingam K, McClure RJ and Levine J,: Brain metabolic effects of acute nicotine. Neurochemical Research, Vol. 26, pp. 181-5, 2001
  74. Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorders. Bipolar Disorders, Vol. 3, pp. 215-232, 2001
  75. Levine J, Chengappa KNR, Patel A, Vagnucci A, John V, Brar JS, Chalasani L, Parepally H, Ganguli R. Obesity and medical illnesses in psychiatric patients admitted to a long-term psychiatric facility. Journal of Psychiatric Practice, Vol. 7, pp. 432-439, 2001
  76. Levine J, Leventhal U, Lerner V, Belmaker RH. Inositol treatment has no effect on the dexamesthasone suppression test. World Journal of Biological Psychiatry, Vol. 2, pp. 190-192, 2001
  77. Parepally H, Chakravorty S, Levine J, Brar JS, Patel AM, Baird JW, Chalasani L, Delaney JA, Atzert R, Chengappa KNR. The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: A naturalistic study at a state psychiatric hospital. Progress in Neuropsychopharmacology & Biological Psychiatry, Vol. 26, pp. 437-40, 2002
  78. Pettegrew JW, Levine J, Gershon S, Stanley J, Servan-Schreiber D, Panchalingam K, McClure RJ. P-MRS study of acetylcarnitine treatment in geriatric depression: preliminary results. Bipolar Disorders, Vol. 4, pp. 61-66, 2002
  79. Chengappa KN, Vasile J, Levine J, Ulrich R, Baker R, Gopalani A, Schooler N, Clozapine: Its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophrenia Research, Vol. 53, pp. 1-6, 2002
  80. Chengappa KN, Chalasani L, Brar J, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther., Vol. 24, pp. 1576-84, 2002
  81. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker R. Elevated homocysteine levels in young male schizophrenic patients. American Journal of Psychiatry, Vol. 159, pp. 1790-1792, 2002
  82. Nemets B, Talesnick B, Belmaker RH, Levine J. Myo-inositol has no beneficial effect on premenstrual dysphoric disorder. World Journal of Biological Psychiatry, Vol. 3, pp. 147-149, 2002
  83. Levine J, Chengappa KN, Ganguli R. Cytokine alterations in schizophrenia: potential treatment implications. essential psychopharmacology. special report 4, Vol. 22, pp. 15-24, 2002
  84. Applebaum J, Levine J, Belmaker RH. Intravenous fosphenytoin in acute mania. Journal of Clinical Psychiatry, Vol. 64, pp. 408-409, 2003
  85. Phrolov K, Applebaum J, Levine J, Miodovnick H, Belmaker RH. Single dose intravenous valproate in acute mania. Journal of Clinical Psychiatry, Vol. 65, pp. 68-70, 2003
  86. Chengappa KN, Golstein JM, Greenwood M, John V, Levine J. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther., Vol. 25, pp. 530-41, 2003
  87. Chengappa KN, Parepally H, Brar J, Gopalani A, Chalasani L, bear J, Levine J. Attitudes towards taking medicine among those patients who either received olanzapine or first generation antipsychotic agents. Indian Journal of Psychiatry, Vol. 45, pp. 151-54, 2003
  88. Levine J, Panchalingam K, McClure RJ, Gershon S, Pettegrew JW. Effects of acetyl-L-carnitine and myo-inositol on high-energy phosphate and membrane phospholipid metabolism in zebra fish: a 31P-NMR-spectroscopy study. Neurochem Res., Vol. 28, pp. 687-90, 2003
  89. Osher Y, Sela B-A, Levine J, Belmaker RH. Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration. Bipolar Disorders, Vol. 6, pp. 82-6, 2004.
  90. Applebaum J, Shimon H, Sela B-A, Belmaker RH, Levine J. Homocysteine levels in newly admitted schizophrenic patients. Journal of Psychiatric Research, Vol. 38, pp. 413-16, 2004
  91. Kozlovsky N, Regenold WT, Levine J, Rapoport A, Belmaker RH, Agam G. GSK-3b in cerebrospinal fluid of schizophrenia patients. Journal of Neural Transmission, Vol. 111, pp. 1093-8, 2004
  92. Levine J , Kaplan Z, Pettegrew JW, McClure RJ, Gershon S, Buriakovsky I, Cohen H. Effect of intraperitoneal acetyl-L-carnitine (ALCAR) on anxiety-like behaviours in rats. Int J Neuropsychopharmacol., Vol. 20, pp. 1-10, 2004
  93. J Levine , G Agam , BA Sela , DL Garver , EF Torrey and RH Belmaker. CSF Homocysteine is not elevated in schizophrenia. J Neural Transmission Vol 112, pp. 297-302, 2005
  94. Stahl Z, Belmaker RH, Friger M, Levine J. Nutritional and life style determinants of plasma homocysteine in schizophrenia patients. Eur Neuropsychopharmacol. Vol 15, pp. 291-5, 2005
  95. Lerner V, Miodownik C, Kaptsan A, Sela BA, and Levine J. High homocysteine serum level in young male schizophrenic and schizoaffective patients with tardive movement disorders – J Clinical Psychiatry. Vol 66, pp 1558-63, 2005
  96. Levine J, Sela BA, Osher Y, Belmaker RH. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry. Vol 29, pp. 1181-91, 2005
  97. Lerner V, Miodownik C, Kaptsan A, Vishne T, Sela BA, Levine J. High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia. J Clin Psychiatry. 2005 Dec;66(12):1558-63
  98. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, BersudskyY, Belmaker RH. Homocysteine reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biological Psychiatry 1;60(3):265-9, 2006
  99. Aviv A, Levine J, Shelef A, Speiser N and Elizur A. Therapist-Patient Sexual Relations: Results of a National Survey in Israel. Isr J Psychiatry Relat Sci. 2006;43(2):119-25.
  100. Bonshtein U, Leiser D and Levine J. Naïve theories in schizophrenia – Are they domain-dependent? J Nerv Ment Dis. 2006 Oct;194(10):753-9.
  101. Lerner V, Libov I, Kaptsan A, Miodownik C, Dwolatzky T, Levine J. The Prevalence of Psychotropic Drug-Induced Tardive Movement Subsyndromes among Israeli Schizophrenic and Schizoaffective Patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci. 2007;44(1):20-8.
  102. Levine J, Gur E, Loewenthal R, Vishne T, Dwolatzky T, van Beynum IM, Sela BA, Vered I, Yosef G, Stein D. Plasma homocysteine levels in female patients with eating disorders. International Journal of Eating Disdorders Int J Eat Disord. 2007 Apr;40(3):277-84.
  103. Miodownik C, Lerner V, Vishne T, Sela BA, Levine J High-dose vitamin B6 decreases homocysteine serum levels in patients with schizophrenia and schizoaffective disorders: a preliminary study. Clin Neuropharmacol. 2007 Jan-Feb;30(1):13-7.
  104. Kaptsan A, Odessky A, Osher Y, Levine J. Lack of efficacy of 5 grams daily of creatine in schizophrenia: a randomized, double-blind, placebo-controlled trial. : J Clin Psychiatry. 2007 Jun;68(6):881-4.
  105. S Roitman, T Green, Y Osher, N Karni and J Levine. Creatine monohydrate in resistant depression: a preliminary study- Bipolar Disorders. 2007,  9:754-8.
  106. Levine J, Timinsky Amital D, Vishne T, Kotler M Kaplan Z,Sela BA, Spivak B, M.D. Elevated Homocysteine Plasma Levels in Male Patients with PTSD- Anxiety and Depression. 2008; 25: E154-7.
  107. Dobrusin M, Weitzman D, Levine J, Kremer I, Reitschel M, Maier W, Belmaker RH,. The Rate of Consanguineous Marriages Among Parents of Schizophrenic Patients in the Arab Bedouin Population in Southern Israel. The World Journal of Biological Psychiatry. 2008 Feb 11:1-3.
  108. Bromberg A, Levine J, Nemetz B, Belmaker RH, Agam G. No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophr Res. 2008 Apr;101(1-3):50-7.
  109. Bromberg A, Bersudsky Y, Levine J, Belmaker RH and Agam G. Global leukocyte DNA methylation is not altered in euthymic bipolar patients. Journal of Affective Disorders. 2009 Nov;118(1-3):234-9.
  110. Shlafman N, Shaldibin S, Applebaum J, Belmaker RH, Levine J. No Gross Abnormality of Plasma Homocysteine After Acute Methionine Loading in Clinically Stabilized Patients with Schizophrenia. Under revision for World Journal of Biological Psychiatry. 2010; ;3(2):64-6.
  111. Ziv I, Leiser D, Levine J. Social cognition in schizophrenia: Cognitive and affective factors. Cogn Neuropsychiatry. 2011; ;16(1):71-91
  112. Bromberg A, Levine J, Belmaker R, Agam G. Hyperhomocysteinemia does not affect global DNA methylation and nicotinamide N-methyltransferase expression in mice. JPsychopharmacol. 2011; l;25(7):976-81.
  113. Todder D, Levine J, Abujumah A, Mater M, Cohen H, Kaplan Z. The quantitative electroencephalogram and the low-resolution electrical tomographic analysis in posttraumatic stress disorder. Clin EEG Neurosci. 2012; ;43(1):48-53.
  114. Levine J, Toder D, Geller V, Kraus M, Gauchman T, Puterman M, Grisaru N.Beneficial effects of caloric vestibular stimulation on denial of illness andmanic delusions in schizoaffective disorder: a case report. Brain Stimul. 2012; ;5(3):267-73
  115. Nemets B, Levine J. A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression. Int Clin Psychopharmacol. 2013,  28(3):127-33
  116. Levine J.  Risk loci with shared effects on major psychiatric disorders. [Letter] Lancet. 2013 Jul 27;382(9889):307.
  117. Geller V, Friger M, Sela BA, Levine J. Elevated homocysteine level in siblings of patients with schizophrenia. Psychiatry Res. 2013 Dec 30;210(3):769-72.
  118. Levental U, Bersudsky Y, Dwalatzky T, Lerner V, Medina S, Levine J. A pilot open study of long term high dose creatine augmentation in patients with treatment resistant negative symptoms schizophrenia. Isr J Psychiatry Relat Sci. 2015;52(1):6-10.
  119. Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, Dean B, Levine J, Agam G, Gozes I. Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry. 2015 Feb;20(1):126-32.
  120. Levine J, Toker L, Agam G. Dissecting disease entities out of the broad spectrum of bipolar-disorders. Psychiatry Research. 2017 Nov 1.
  121. Todder D, Gershi A, Perry Z, Kaplan Z, Levine J, Avirame K. Immediate Effects of Transcranial Direct Current Stimulation on Obsession-Induced Anxiety in Refractory Obsessive-Compulsive Disorder: A Pilot Study. The journal of ECT. 2017 Dec.
  122. Levine J, Cohen D, Herman C, Verloes A, Guinchat V, Diaz L, Cravero C, Mandel A, Gozes I. Developmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation. J Mol Neurosci. 2019 May 24. doi:10.1007/s12031-019-01333-9.
  123. Bar-Yosef T, Hussein W, Yitzhaki O, Damri O, Givon L, Marom C, Gurman V, Levine J, Bersudsky Y, Agam G, Ben-Shachar D. Mitochondrial function parameters as a tool for tailored drug treatment of an individual with psychosis: a proof of concept study. Scientific RepoRtS. 2020 Jul 23;10(1):1-1.
  124. Levine, J., Lobyntseva, A., Shazman, S. et al. Longitudinal Genotype-Phenotype (Vineland Questionnaire) Characterization of 15 ADNP Syndrome Cases Highlights Mutated Protein Length and Structural Characteristics Correlation with Communicative Abilities Accentuated in Males. J Mol Neurosci 74, 15 (2024).


  1. Levine Y, Gaony B. The hypoparathyriod syndrome: A Psychiatric point of View . Isr. J. Psychiat., Vol. 27, pp. 242-6, 1990
  2. Caspi N, Levine J. Electroconvulsive treatment of akathisia: a case report. Ist.J.Psychiat., Vol. 30, pp. 175-8, 1992
  3. Levine J, Avramovitch A. Tape recording usage in the treatment of paranoid patient. Israel Journal of Psychotherapy: "Sihot", Vol. 7, pp. 222-226, 1993
  4. Levine J, Caspi N, Barak, Y. The influence of cognitive dissonance induction on the resolution of paranoid system in a paranoid schizophrenic patient. Israel Journal of Psychotherapy "Sihot", Vol. 8, pp. 208-211, 1994
    4b. Levine J, Barak Y, Caspi N. Cognitive dissonance in the treatment of paranoid schizophrenia. J. Cognitive Psychother., Vol. 9, pp. 251-262, 1995
  5. Levine J, Susnosky M, Handze TZ, Leykin I, Shinitzky M. Azathioprine treatment of refractory schizophrenia. Lancet, Vol. 344, pp. 59-60, 1994 (extended peer-reviewed letter – 2 pages)
  6. Levine J, Wiztum E, Greenberg B, Barak Y. Inositol might induce mania. Am. J. Psychiatry, Vol. 153, pp. 839, 1996 (peer-reviewed letter)
  7. Levine J, Cholestoy A, Zimmerman J. Possible antidepressant effect of minocycline. Am. J. Psychiat., Vol. 153, pp. 582, 1996 (peer-reviewed letter)
  8. Barak Y, Levine J, Weisz P. Clozapine induced myoclonus : Two case reports. J Clinical Psychopharmacology, Vol. 16, pp. 339-40, 1996
  9. Levine J, Chengappa KRN. Side-effect profile of enteric coated divalproex sodium versus valproic acid. Journal of Clinical Psychiatry, Vol. 61, pp. 680-681, 2000 (extended peer-reviewed letter)
  10. Amital D, Vishne T, Roitman S, Kotler M and Joseph Levine J. Open Study of Creatine Monohydrate in Resistant PTSD (extended Letter). J Clin Psychiatry – in press
  11. Levine J, Belmaker RH Osteoporosis in schizophrenia. Am J Psychiatry. 2006 Mar;163(3):549-50
  12. Amital D, Vishne T, Rubinow A, Levine J. Observed effects of creatine monohydrate in a patient with depression and fibromyalgia. Am J Psychiatry. 2006 Oct;163(10):1840-1
  13. Amital D, Vishne T, Roitman S, Kotler M, Levine J. Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder. J Clin Psychiatry. 2006 May;67(5):836-7
  14. Levine J, Chengappa KN. Exposure to nitrous oxide may be associated with high homocysteine plasma levels and a risk for clinical depression. J Clin Psychopharmacol. 2007 Apr;27(2):238-9.
  15. Todder D., Levine J., Dwolatzky T., Kaplan Z., Impaired memory and disorientation induced by delta band down-training over the temporal brain regions by neurofeedback treatment. Journal of Neurotherapy, 14, 2, 2010.


  1. Treiman N, Levy A, Levin Y, Neumann M. 100 years' quest for objective diagnosis of schizophrenia. Harefuah (Heb.), Vol. 114, pp. 144-147, 1988
  2. Ben-Artzi E, Levy A, Levin Y, Neumann M. Inter- and intra-hemispheric asymmetry in schizophrenia Harefuah (Heb.), Vol. 120, pp. 34-37, 1990 .
  3. Levkovitch Y, Levy A, Levin Y, Neumann M. Sudden death of psychiatric patients Harefua (Heb.), Vol. 119, pp. 323-326, 1990
  4. Etzion T, Levy A, Levin Y, Neumann M. Should electroconvulsive therapy be used as an ambulatory preventive treatment. Isr. J. Psychiat., Vol. 27, pp. 168-17, 1990
  5. Levin Y, Ben-Artzi E, Levy A, Neumann M. Traffic Accidents and Psychiatric Disturbances Harefuah (Heb.), Vol. 121, pp. 125-7, 1991
  6. Nachshony T Levy A, Levin Y, Neumann M. Negative symptoms in schizophrenia. Harefua (Heb.), Vol. 124, pp. 692-695, 1993
  7. Levine J and Grisaru N,: Hallucinations. Harefua(Heb.), Vol. 127, pp. 261-265, 1994
  8. Ring A, Barak Y, Levine J. Diets for ADDH Harefua(Heb.), Vol. 128, pp. 505-9, 1995
  9. Levine J , Grisaru N. Inositol treatment in medicine. Harefuah (Heb.), Vol. 130, pp. 630-634, 1996
  10. Belmaker RH, Bersudsky Y, Benjamin J, Agam G, Levine J, Kofman O. Manipulation of inositol-linked second messenger systems as a therapeutic strategy in psychiatry. Advances in Biochemical Psychopharmacology, Vol. 49, pp. 67-84, 1995
  11. Levine J. Inositol trials in psychiatry. Eur. Neuropsychopharmacology, Vol. 7, pp. 147-155, 1997
  12. Agam G, Levine J. Glycogen synthase kinase-3 – A new target for lithium’s effects in bipolar patients. Human Psychopharmacology, Vol. 13, pp. 463-65, 1998
  13. Levine J, Chengappa KN, Gershon S, Drevets W. Differentiating primary pathophysiologic from secondary adaptational processes. Depression & Anxiety, Vol. 14, pp. 105-11, 2001
  14. Levine J, Cole DP, Chengappa KN, Gershon S. Anxiety disorders and major depression, together or apart. Depression & Anxiety, Vol. 14, pp. 94-104, 2001
  15. Himmelhoch J, Levine J, Gershon S. Historical overview of the relationship between anxiety disorders and affective disorders. Depression & Anxiety, Vol. 14, pp. 53-66, 2001
  16. Belmaker RH, Levine J, Nemets B, Fux M. Combination of Antidepressant Drugs: The Case of Inositol. Human Psychopharmacology, Vol. 16, pp. 37-43, 2001
  17. Levine J, Bottiglieri T, Belmaker RH. Introduction to special issue. Prog Neuropsychopharmacol Biol Psychiatry. Vol 29, pp. 1101-2, 2005
  18. Levine J, Toser D, Zeev K. [Between neurology and psychiatry]. Harefuah. 2014  Jun;153(6):346-51, 366.


    1. Levine J, Gonsalves M, Belmaker RH. Inositol modulation of second messenger systems: A strategy for psychopharmacology of depression in aging. in: Psychopharmacolgy in the elderly: principals of research and clinical implications. Bergner, Tropper, Belmaker (Eds), Springer Publishing Company, NY, pp. 254-262, 1993.
    2. Shwartz M, Rapoport A, Stein D, Levine J, Stier S, Elizur A, Sarova I, Deprenil treatment of neuroleptic induced parkinonism: International symposium: dementia in parkinson's disease. Monduzzi editore – division of international proceedings, Bologna, Italy,1994
    3. Belmaker RH, Bersudsky Y, Benjamin J, Agam G, Levine J, Kofman O. Manipulation of inositol – linked second messenger systems as a therapeutic strategy in psychiatry in: G.L.Gessa, W.Fratta, L.Pani, G.Serra (Eds.). Depression: Neurobiology, pharmacology and clinic. Raven press, NY, Vol 46, pp. 67-84, 1995
    4. Belmaker RH, Bersudsky Y, Agam G, Levine J, Kaufman O. How does lithium work on manic- depression: clinical and psychological correlates of the inositol theory. Annual Re. Med., Vol. 47, pp. 47-56, 1996
    5. Levine J, Barak Y, Benjamin J, Bersudsky Y, Kaufman O, Belmaker RH. Therapeutic potential of inositol treatment in depression, panic and dementia and lithium side-effects. in: Pharmacotherapy of mood and cognition. S. Montgomery & U. Halbrech. ( Eds.) American Psychiatric Press Inc., Washington D.C., pp. 159-166, 2000
    6. Chengappa KNR, Levine J. Biological treatments for bipolar disorder: Recent strategies. In: Andrade C (ed): Advances in Psychiatry. Oxford University Press, New Delhi, 2000, pp. 215-240, 2000
    7. Antelman SM, Levine J, Gershon S, Edwards DJ, Caggiula AR. Is inositol likely to be effective in treating bipolar disorder? A prediction from a cycling model of the illness. In: Soares JC, Gershon S (eds.) Basic mechanisms and therapeutic implications of bipolar disorder. Marcel Dekker , Inc., NY, pp. 49-58, 2000
    8. Levine J, Gershon S. Prophylactic medications in psychiatry (4000 words). International Encyclopedia of the social and behavioral sciences. 26 volumes. Editors in Chief, Smelser NJ & Baltes PB. Section Editor (psychiatry) Melvin Sabshin & Florian Holsboer. Pergamon, press, London, 2001
    9. Chengappa KNR, Levine J. The use of newer anticonvulsant agents for bipolar disorders. In: Vieta E (ed): Bipolar disorders: clinical and therapeutic progress. Editorial medica, Boenos Aires, pp 1-14, 2001
    10. Levine J, Soares J, Chengappa KRN, Gershon S. Lithium in the treatment of bipolar disorder. In: Yatham LN, Kusumakar V, Kutcher S (eds). Bipolar disorder: a clinician guide to biological treatment. Brunner-Routledge, New York, pp. 139-168, 2002
    11. Pettegrew JW, Levine J, McClure RJ. 2002. Acetyl-L-carnitine in mood, aging and disease. In: Mattson MP Diet-Brain Connections: Impact on Memory, Mood, Aging and Disease. Kluwer Academic Publisherrs, Boston. pp: 159-178, 2002
    12. Levine J, Bersudsky Y, Nadri C, Yaroslavsky Y, Abed N, Mishory A, Agam G, Belmaker RH, 2003: Mechanism of action of new mood stabilizing drugs In: Handbook of Medical Psychiatry. Soares JC and Gershon S (eds) Marcel Dekker, New York, pp. 793-806, 2003
    13. Novel treatments in bipolar depression Levine J, Appelbaum J, Belmaker RH. Chapter in: Bipolar Depression: Americam Psychiatric Press. PP: 191-214. Editors: El-Mallakh RS, & Nassir Ghaemi, 2006
    14. Levine J, Chengappa KRN. Lithium in the treatment of bipolar disorder. In: Yatham LN, Kusumakar V, Kutcher S (eds). Bipolar disorder: a clinician guide to biological treatment. Brunner-Routledge, New York, Second edition, 2007
    15. Belamker RH Levine J. Inositol in the treatment of psychiatric disorders. (pp: 105-118) in: Mischoulon D & Rosenbaum JF (eds.) Alternative medications and treatment of psychiatric disorders, Second Edition, Lippincoptt Williams & Wilkins, 2008
    16. סוזנה רויטמן ויוסף לוין: הסכמה מדעת לטיפולים מיוחדים עם הדגש אודות הטיפול בנזעי חשמל בספרם של אלכסנדר גרינשפון, אליעזר ויצטום, עמיחי לוי, משה קליאן.     פסיכיאטריה משפטית בישראל. (2009) הוצאה לאור: אריה ניר
    17. Levine J, R Ebstein, Kremer I, RH Belmaker. Genetic epidemiology of schizophrenia in Arab communities in Isreal. in: I Levav (Ed.) Psychiatric and behavioral disorders in Israel. reen Publishing House. pp:254-266. 2009.
    18. Levine J, Bromberg A, Dwolatzky T. Homocysteine as a risk factor in schizophrenia. In:. Food supplements – a new hope for schizophrenia and mood disorders. Lerner V, Miodownik C (Eds), Nova Science Publishers, Inc. New York. 2009.
    19. אודסקי אלכס, ואדים גילר, פלטניק אלכס, לוין יוסף  – הפרעות דלוזיונליות ופסיכוזות בזקנה  בספר: פרקים נבחרים בפסיכוגריאטריה בעריכת ירמיהו הייניק וצבי דווליצקי    2015 .
    20. Levine J. Clinical convergence of autism, schizophrenia and Alzheimer’s disease: The case of social cognition. Gozes I & Levine J (Eds.) Neuroprotection in Autism, Schizophrenia and Alzheimer's disease. Academic Press. NY. 2019
    21. Agam G, Levine J. Neuroprotective effects of lithium in neuropsychiatric disorders. Gozes I & Levine J (Eds.) Neuroprotection in Autism, Schizophrenia and Alzheimer's disease. Academic Press. NY. 2019


  1. Bauer A, Levin Y. The consultant psychiatrist and the family physician: similarities and differences. The family physician (Heb.) Vol. 19, No. 3, 1991
  2. Levine J, Pomerantz T, Belmaker RH. The effect of inositol on cognitive processes and mood states in normal volunteers. Eur. psychopharmacol. Vol. 4, pp. 418-19, 1994
  3. Barak Y ,Levine J ,Belmaker RH. Effect of inositol on lithium induced EEG abnormalities. Eur. psychopharmacol., Vol. 4, pp. 419-420, 1994 (original research data not published elsewhere)
  4. Levine J. Conditions for research in biological psychiatry. Isr. J. Psychiat. Vol. 32, pp. 151-151, 1995 (Let.)
  5. Levine J, Chengappa KRN. Second thought about clozapine as a treatment for neuroleptic induced akathisia (letter with original research data- peer-reviewed). J Clinical Psychiatry, Vol. 59, pp. 195, 1998 (Let.)
  6. Antelman S, Levine J Caguilla A, Gershon S. Pills or placebos? Science, Vol. 284, pp. 913-4, 1999 (Let.)
  7. Levine J, Chengappa KN, Gershon S. Editorial for special issue on the relationship between anxiety and depression. Depress. & Anxiety, Vol. 14, pp. 51-52, 2001
  8. Levine J, Panchalingam K, McClure RJ, Gershon S, and. Pettegrew JW,: Effects of acetylcarnitine and myoinositol on phosphorous energy metabolism in zebra fish: a 31P-NMR spectroscopy study. European Neuropsychopharmacology. Conference Proceedings. European Neuropsychopharmacology, Vol. 11, pp. S159, 2001
  9. Levine J: Book on Impulse Disorders (in Hebrew). Prolog LTD, Isreal (in press, 130 pages, 2005) פרופ' לוין יוסף: להתמודד עם היצר – ספר בהוצאת פרולוג על הפרעות הדחף (130עמוד, 2005)


  1. Levine J, Gershon S Chengappa KN (Eds.). Relationship between anxiety and depression. Anxiety and depression Vol 14, 2001, pp. 51-111 (also co-author of 3 manuscripts in this special issue)
  2. Levine J, Bottiglieri T AN Belmaker RH (Eds.) Homocysteine and MTHFR in psyciatric disorders. Editors of a special issue of Prog Neuropsychopharmacol & Biol Psychiatry (Vol 29 (7), pp. 1101-1191, 2005)
  3. Levine J (Guest Editor). Special Issue on Autism, Psychiatric Disorders and Neurodegenerative Diseases. Journal of Molecular Neuroscience, Volume 70, Number 2, February 2020.


Neuroprotection in Autism, Schizophrenia and Alzheimer's disease (Link to blog post)

Editors: Illana Gozes & Joseph Levine

ISBN: 9780128140376

Academic Press  NY. Scheduled to appear on November 2019.

Publishing Date: 1st November 2019